Functional cure of HIV: the scale of the challenge
- PMID: 30410126
- DOI: 10.1038/s41577-018-0085-4
Functional cure of HIV: the scale of the challenge
Abstract
A variety of interventions to induce a functional cure of HIV are being explored, with the aim being to allow patients to cease antiretroviral therapy (ART) for prolonged periods of time or for life. These interventions share the goal of inducing ART-free remission from HIV pathogenesis and disease progression but achieve this in quite different ways, by reducing the size of the latent reservoir (for example, small-molecule stimulation of latently infected cells), reducing the number of target cells available for the virus (for example, gene therapy) or improving immune responses (for example, active or passive immunotherapy). Here, we consider a number of these alternative strategies for inducing post-treatment control of HIV and use mathematical modelling to predict the scale of the challenge inherent in these different approaches. For many approaches, over 99.9% efficacy will likely be required to induce durable ART-free remissions. The efficacy of individual approaches is currently far below what we predict will be necessary, and new technologies to achieve lifelong functional cure are needed.
Similar articles
-
Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.Curr HIV/AIDS Rep. 2020 Jun;17(3):237-248. doi: 10.1007/s11904-020-00495-1. Curr HIV/AIDS Rep. 2020. PMID: 32356090 Free PMC article. Review.
-
HIV reservoirs as obstacles and opportunities for an HIV cure.Nat Immunol. 2015 Jun;16(6):584-9. doi: 10.1038/ni.3152. Nat Immunol. 2015. PMID: 25990814
-
Posttreatment controllers: what do they tell us?Curr Opin HIV AIDS. 2015 Jan;10(1):29-34. doi: 10.1097/COH.0000000000000123. Curr Opin HIV AIDS. 2015. PMID: 25402707 Review.
-
HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.J Virol. 2018 Mar 14;92(7):e02118-17. doi: 10.1128/JVI.02118-17. Print 2018 Apr 1. J Virol. 2018. PMID: 29343582 Free PMC article.
-
A cure for HIV: is it in sight?Expert Rev Anti Infect Ther. 2014 Jul;12(7):783-91. doi: 10.1586/14787210.2014.910112. Epub 2014 Apr 19. Expert Rev Anti Infect Ther. 2014. PMID: 24745361 Review.
Cited by
-
Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators.J Med Chem. 2023 Dec 14;66(23):16303-16329. doi: 10.1021/acs.jmedchem.3c01647. Epub 2023 Dec 6. J Med Chem. 2023. PMID: 38054267 Free PMC article.
-
Why and where an HIV cure is needed and how it might be achieved.Nature. 2019 Dec;576(7787):397-405. doi: 10.1038/s41586-019-1841-8. Epub 2019 Dec 18. Nature. 2019. PMID: 31853080 Free PMC article. Review.
-
Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV.ACS Omega. 2021 Jun 8;6(25):16524-16534. doi: 10.1021/acsomega.1c01721. eCollection 2021 Jun 29. ACS Omega. 2021. PMID: 34235324 Free PMC article.
-
Persistent hepatitis B virus and HIV coinfections in dually humanized mice engrafted with human liver and immune system.J Med Virol. 2023 Jul;95(7):e28930. doi: 10.1002/jmv.28930. J Med Virol. 2023. PMID: 37403703 Free PMC article.
-
Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells.Autophagy. 2022 Jun;18(6):1256-1273. doi: 10.1080/15548627.2021.1972403. Epub 2021 Oct 6. Autophagy. 2022. PMID: 34612140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
